Mizuta Einosuke, Hamada Toshihiro, Igawa Osamu, Shigemasa Chiaki, Hisatome Ichiro
Division of Molecular Medicine and Therapeutics, Department of Multidisciplinary Internal Medicine, Tottori University Faculty of Medicine, Japan.
Clin Calcium. 2010 Jan;20(1):45-50.
In hypertensive subjects, their serum uric acid levels tend to be higher because of decreasing urinary secretion or overproduction of uric acid. Among calcium channel blockers (CCBs) , long acting nifedipine and cilnidipine reveal serum uric acid lowering action. They decrease the production of uric acid precursor in skeletal muscles under anaerobic condition induced by hypertension or insulin resistance. Hyperuricemia is considered to be a risk factor of not only gout but also renal and cardiovascular diseases, thus, it is important to use CCBs without adverse effect on uric acid metabolisms.
在高血压患者中，由于尿酸分泌减少或尿酸生成过多，他们的血清尿酸水平往往较高。在钙通道阻滞剂（CCB）中，长效硝苯地平和西尼地平具有降低血清尿酸的作用。它们可减少高血压或胰岛素抵抗诱导的无氧条件下骨骼肌中尿酸前体的生成。高尿酸血症不仅被认为是痛风的危险因素，也是肾脏和心血管疾病的危险因素，因此，使用对尿酸代谢无不良影响的CCB很重要。
